ヘパリン吸収に対する皮膚の厚さの影響
C Kroon1, A de Boer, J M Kroon
1Centre for Human Drug Research, University Hospital, Leiden, Netherlands.
Lancet (London, England)
|April 20, 1991
まとめ
皮下注射によるヘパリンの吸収は,腹部の皮膚の厚さに関連して,個別の有意な変動を示しています. この発見はヘパリン療法と予防策に影響を及ぼします.
科学分野:
- 薬理学 薬理学とは
- バイオケミストリー バイオケミストリー
背景:
- ヘパリンは,広く使用されている抗凝固剤です.
- ヘパリン吸収の理解は,有効な投与のために非常に重要です.
研究 の 目的:
- 高分子量および低分子量ヘパリン分子の皮下吸収を評価するために.
- ヘパリン吸収の変動に影響を与える要因を特定する.
主な方法:
- 健康な男性8人は,ヘパリンを静脈内および皮下投与した.
- 抗凝固剤は,抗Xa,抗トロンビン活性,および活性化された部分的血栓プラスティン時間によって監視されます.
- 体重,脂肪,皮の厚さなどを記録した.
主要な成果:
- 高分子量および低分子量ヘパリン分子の両方に類似した吸収が観察されました.
- 皮膚下ヘパリン吸収における個別間での有意な変動.
- 腹部皮質の厚さは吸収の変動と相関しています.
結論:
- 皮膚下ヘパリンの吸収は,個人によって非常に変動します.
- 腹部皮質の厚さはヘパリン吸収に影響を与える重要な要因です.
- これらの発見は,ヘパリンによる治療および予防療法の最適化への影響を及ぼします.
関連する概念動画
Factors Influencing Drug Absorption: Anatomical Parameters
Drug absorption involves the movement of drugs from the point of administration into the systemic circulation. Initially, Gastrointestinal (GI) motility propels the drug through the digestive tract and into the stomach. However, the stomach's high acidity and limited surface area restrict its role in drug absorption for most drugs. The drug then moves from the stomach to the small intestine via gastric emptying, which can be slowed by various factors, including interactions with other...
Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


